Spermosens adjusts publication date for Year-end report 2024
Spermosens AB (publ) announces that the company’s Year-end report for 2024, originally scheduled for publication on February 12, 2025, has been postponed to February 13, 2025. The adjustment has been made to align with the calendar availability of the company’s Board of Directors.
For more information, please contact
Tore Duvold, CEO
Spermosens AB is a pioneering biotechnology company dedicated to advancing fertility treatments through innovative diagnostic solutions. Based in Sweden, Spermosens specializes in developing cutting-edge technologies that improve fertility outcomes and simplify the treatment process for individuals and couples facing infertility challenges. The proprietary JUNO-Checked product aims to enhance the precision and effectiveness of fertility diagnostics, ultimately helping more people achieve their dream of parenthood. Committed to scientific excellence and patient care, Spermosens collaborates with leading research institutions and commercial partners to bring transformative solutions to the market. The company's shares are listed on the Spotlight Stock Market. The shares have ISIN code SE0015346424 and are traded under the short name SPERM. For more information, see www.spermosens.com